Generate QR code
Open Access
Subscription Access
Idiopathic thrombocytopenic purpura
https://doi.org/10.30629/0023-2149-2024-102-4-309-314
Abstract
The review presents a modern understanding of the pathophysiology and mechanisms leading to thrombocytopenia, as well as emerging treatment methods for.
About the Authors
T. I. Avdeeva
North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of Russia
Russian Federation
Russian Federation
Tatyana I. Avdeeva — resident, Department of Transfusiology
St. Petersburg
A. V. Koloskov
North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of Russia
Russian Federation
Russian Federation
Andrey V. Koloskov — Dr. of Sci. (Med.), Professor, Head of the Department of Transfusiology
St. Petersburg
References
1. Boylan B., Hong C., Vipul R., Cathy P., Michael S., Kenneth D.F. et al. Anti-GPVI–associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface.Blood. 2004;104(5):1350– 1355. DOI: 10.1182/blood-2004-03-0896
2. Melikyan A.L., Pustovaya E.I., Tsvetaeva N.V., Ptushkin V.V., Gritsaev S.V., Golenkov A.K. et al. National clinical recommendations for diagnosis and therapy of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) in adults. Hematology and Transfusiology. Russian journal (Gematologiya i Trasfusiologia). 2017;60(1):44 –56. (in Russian).
3. Grodzielski M., Goette N.P., Glembotsky A.C., Pietto M.C.B., Méndez-Huergo S.P., Pierdominici M.S., et al. Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Scientifi c Reports. 2019;9(1):2208. DOI:10.1038/s41598-018-38086-1
4. Matzdorff A., Meyer O., Ostermann H., Kiefel V., Eberl W., Kühne T. et al. Immune thrombocytopenia-current diagnostics and therapy: recommendations of a joint working group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncology Research and Treatment. 2018;41(Suppl. 5):1 –30. DOI: 10.1159/000492187
5. Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfusion. 211;9(3):262. DOI: 10.2450/2010.0080-10
6. Arnold D.M. Immune thrombocytopenia: getting back to basics. American Journal of Hematology. 2012;87(9):841. DOI: 10.1002/ajh.23287
7. Sun S., Urbanus R.T., Ten Cate H., de Groot P.G., de Laat B., Heemskerk J.W.M. et al. Platelet activation mechanisms and consequences of immune thrombocytopenia. Cells. 2021;10(12):3386. DOI: 10.3390/cells10123386
8. Efficace F., Mandelli F., Fazi P., Santoro C., Gaidano G., Cottone F. et al. Health‐related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. American Journal of Hematology. 2016;91(10):995 –1001. DOI: 10.1002/ajh.24463
9. Efat A., Shoeib S., Nazir A., Abdelmohsen E., Dawod A., Bedair H.M. et al. Endothelial activation and Immune Thrombocytopenia: an Engagement Waiting for consolidation. Clinical and Applied Thrombosis/Hemostasis. 2021;27:10760296211054514. DOI: 10.1177/10760296211054514
10. Vaillant A.J., Gupta N. ITP-immune thrombocytopenic purpura. Stat Pearls. 2023.
11. Mehic D., Machacek J., Schramm T., Buresch L., Kaider A., Eichelberger B. et al. Platelet function and soluble P-selectin in patients with primary immune thrombocytopenia. Thrombosis Research. 2023;223:102 –110. DOI: 10.1016/j.thromres.2023.01.012
12. Wang L., Wang D.D., Jiao R.Y., Liu C.X., Hou Y.Q., Qin H. et al. Association between P-Selectin autoantibody positive and response to steroid treatment in newly diagnosed immune thrombocytopenia patients. Acta Haematologica. 2022;145(5):499–504. DOI: 10.1159/000524535 DOI: 10.1002/ajh.24463
13. Singh A., Uzun G., Bakchoul T. Primary immune thrombocytopenia: novel insights into pathophysiology and disease management. Journal of Clinical Medicine. 2021;10(4):789. DOI: 10.3390/jcm10040789
14. Anat G.G. Current approaches for the diagnosis and management of immune thrombocytopenia. European Journal of Internal Medicine. 2022;108 (2023):18 –24. DOI: 10.1016/j.ejim.2022.11.022
15. Miltiadous O., Hou M., Bussel J.B. Identifying and treating refractory ITP: diffi culty in diagnosis and role of combination treatment. Blood. The Journal of the American Society of Hematology. 2020;135(7):472 –490. DOI: 10.1182/blood.2019003599
16. Liu X., Hou Y., Hou M. How we treat primary immune thrombocytopenia in adults. Journal of Hematology and Oncology. 2023;16(1):1–20. DOI: 10.1186/s13045-023-01401-z
17. Vianelli N., Auteri G., Buccisano F., Carrai V., Baldacci E., Clissa C. et al. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Annals of Hematology. 2022;101(5):963 –978. DOI: 10.1007/s00277-022-04786-y
18. Terrell D.R., Neunert C.E., Cooper N., Heitink-Pollé K.M., Kruse C., Imbach P. et al. Immune thrombocytopenia (ITP): current limitations in patient management. Medicina. 2020;56(12):667. DOI:10.3390/medicina56120667
Review
For citations:
Avdeeva T.I., Koloskov A.V. Idiopathic thrombocytopenic purpura. Clinical Medicine (Russian Journal). 2024;102(4):309-314. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-4-309-314
Views:
317
Email this article 